1. Home
  2. NCRA vs IMNN Comparison

NCRA vs IMNN Comparison

Compare NCRA & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

N/A

Current Price

$0.73

Market Cap

12.3M

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.55

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
IMNN
Founded
2002
1982
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
12.5M
IPO Year
N/A
1985

Fundamental Metrics

Financial Performance
Metric
NCRA
IMNN
Price
$0.73
$3.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
53.4K
76.9K
Earning Date
04-01-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$2.99
52 Week High
$2.40
$41.22

Technical Indicators

Market Signals
Indicator
NCRA
IMNN
Relative Strength Index (RSI) 37.82 47.02
Support Level $0.82 $3.39
Resistance Level $0.96 $3.77
Average True Range (ATR) 0.10 0.24
MACD -0.01 -0.01
Stochastic Oscillator 0.03 29.27

Price Performance

Historical Comparison
NCRA
IMNN

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: